The most frequent mutation is in EGFR, and inhibitors targeting the structural domain of the EGFR kinase, EGFR-TKIs, have been developed as the standard first-line treatment for patients with EGFR mutations in advanced NSCLC, achieving excellent results in terms of progression-free survival and OS [98]. Here, EGFR is linked to non-small cell lung carcinoma.